IP Library Granted Patent US 9,221,903
Granted Patent B2
US 9,221,903 · App. 14/090,183 · Granted Dec 29, 2015

Method of inhibiting binding or activity of MIF by administering a MIF antagonist

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,221,903
App. No.
14/090,183
Granted
Dec 29, 2015
Kind
B2
Abstract

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

Claims (9)

1. A method of inhibiting the binding of macrophage migration inhibitory factor (MIF) on a cell comprising on the surface an MHC class II invariant chain (Ii) polypeptide, said method comprising:

contacting said cell with an antagonist of MIF wherein said antagonist is a recombinant polypeptide comprising a MIF protein-binding fragment of the amino acid sequence of SEQ ID NO:2, and wherein said cell is present in a mammal suffering from a B cell cancer, thereby inhibiting the binding of MIF to said Ii polypeptide.

2. A method according to claim 1 wherein said antagonist is labeled with an antibody or fragment thereof.

3. A method according to claim 1 or 2 , wherein said antagonist is administered to the mammal in a pharmaceutical composition.

4. A method according to claim 3 , wherein said antagonist is administered in an amount effective to treat the B cell cancer.

5. A method according to claim 1 , wherein said recombinant polypeptide is a soluble form.

6. A method according to claim 5 , wherein said soluble form comprises amino acids 73-232 of SEQ ID NO: 2.

7. A method according to claim 5 , wherein said soluble form comprises amino acids 110-149 of SEQ ID NO: 2.

8. A method according to claim 1 , wherein said cell is present in a mammal suffering from a B-cell lymphoma.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036368/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036379/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2014
From: CYTOKINE PHARMASCIENCES, INC.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 031894/0106 →